David Letzer, MD
Infectious Disease · Brookfield, WINPI 1255382529
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,587 of the $4,223 with a category attached, or 61.2%. 21 manufacturers reported payments, led by Melinta Therapeutics, LLC at 26.6% of the total. Reporting peaked in 2021 at $1,579 and has fallen 60.6% since, to $623 in 2025. Among infectious disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$1K
- AbbVie$996
- Insmed, Inc.$491
- Viiv Healthcare Company$278
- Astellas Pharma US Inc$260
- Merck$186
- plus $890 from 15 others
What the payments were for
- Consulting fees$1,05025%
- Food & beverage$2,58761%
- Education$58714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 5 | $1,122 |
| AbbVie(2 entities) | 88 | $996 |
| Insmed, Inc. | 18 | $491 |
| Viiv Healthcare Company | 14 | $278 |
| Astellas Pharma US Inc | 7 | $260 |
| Merck | 8 | $186 |
| Ferring Pharmaceuticals Inc. | 3 | $138 |
| Gilead | 6 | $128 |
| Theratechnologies Inc. | 4 | $105 |
| Janssen Products, LP | 1 | $89 |
| La Jolla Pharmaceutical Company | 3 | $75 |
| Shionogi Inc | 3 | $58 |
| Janssen Scientific Affairs, LLC | 2 | $52 |
| Johnson & Johnson | 2 | $50 |
| EMD Serono, Inc. | 2 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Pfizer | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,223 in reported general payments places this provider in the 95th percentile of 133 infectious disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 60 | $260,443 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $99,546 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $76,631 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 21 | $74,042 |
| IsentressRaltegravir Potassium | 25 | $54,192 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| TivicayDolutegravir Sodium | 18 | $37,733 |
| Isentress HdRaltegravir Potassium | 12 | $27,618 |
| ErtapenemErtapenem Sodium | 44 | $13,220 |
| Daptomycin | 20 | $6,270 |
| Vancomycin Hcl | 51 | $5,802 |
| Cephalexin | 115 | $5,365 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 23 | $3,463 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $2,372 |
| Fosfomycin Tromethamine | 25 | $2,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $128 | $308,46672 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Triumeq, Tivicay | $278 | $287,95176 claims |
| MerckIsentress, Isentress Hd | $186 | $81,81137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 infectious disease providers in Wisconsin.
Other infectious disease in Brookfield
- William TimmBrookfield$4K
- Jennifer HongBrookfield$2K
- Thomas TaftBrookfield$135
- James LevinMadison$167K
- Edward MoralesGreen Bay$82K
- Robert StrikerMadison$80K
- Shravan KethireddyMadison$22K
- Nasia SafdarMadison$22K
- David AndesMadison$20K
- Krishna BobbiliSheboygan$942
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.